Cannabinoid
THC for HIV/AIDS
HIV Neurobehavioral Research Program (HNRP), San Diego, CA
Targeting 6 different conditionsTHC +1 morePhase 2Waitlist AvailableLed by Ronald J Ellis, MD, PhDResearch Sponsored by University of California, San DiegoEligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Experience with THC-containing cannabis use at least once in the past 5 years without major adverse effects (e.g., psychosis, syncope)
No or low cannabis use in the past 6 months, defined as no cannabis exposure or use or use limited to only once per month in the past 6 months
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upchange from week 4 to week 6
Awards & highlights
No Placebo-Only Group
Study Summary
This trial will study the effects of cannabis use and HIV on the brain and inflammation. Participants will be given the same treatment in a different order over 6 weeks to monitor safety and measure the effects of the drug.
Eligible Conditions
- HIV/AIDS
- Cannabis
- Tetrahydrocannabinol
- Neuroinflammatory Disease
- Neuroinflammatory Response
- Microbiome
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
You have used cannabis with THC in it at least once in the past 5 years without any serious negative effects like hallucinations or fainting.
Select...
You have not used cannabis in the past 6 months, or if you have, it has been very limited, like only using it once a month.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from week 4 to week 6
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week 4 to week 6
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
PC1
Secondary outcome measures
blood-brain barrier (BBB)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: THC first, then CBDExperimental Treatment2 Interventions
THC 10mg + placebo daily for 2 weeks, followed by washout for 2 weeks, followed by CBD 600mg + placebo daily for 2 weeks
Group II: CBD first, then THCActive Control2 Interventions
CBD 600mg + placebo daily for 2 weeks, followed by washout for 2 weeks, followed by THC 10mg + placebo daily for 2 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
THC
2017
Completed Phase 1
~330
CBD
2017
Completed Phase 2
~410
Find a site
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,077 Previous Clinical Trials
1,843,122 Total Patients Enrolled
Ronald J Ellis, MD, PhDPrincipal Investigator
UC San Diego2 Previous Clinical Trials
132 Total Patients Enrolled
Media Library
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still available slots for those wishing to partake in this research?
"Per the information posted on clinicaltrials.gov, this research is not actively recruiting participants at present. The trial was first announced October 1st 2022 and last updated September 14th of that same year. Even though this investigation has halted recruitment for now, there are still 450 other studies seeking volunteers presently."
Answered by AI
Has the Food and Drug Administration sanctioned THC for medicinal use?
"In our assessment, THC's safety was rated a 2 due to its Phase 2 trial status. This indicates that there is some information on the drug's security but none demonstrating effectiveness."
Answered by AI
Recent research and studies